Cleared Traditional

PulsioFlex Monitoring System (K172259) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K172259 · Pulsion Medical Systems SE · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2018
Decision
175d
Days
Class 2
Risk

K172259 is an FDA 510(k) clearance for the PulsioFlex Monitoring System. Classified as Computer, Diagnostic, Pre-programmed, Single-function (product code DXG), Class II - Special Controls.

Submitted by Pulsion Medical Systems SE (Feldkirchen, DE). The FDA issued a Cleared decision on January 18, 2018 after a review of 175 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1435 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Pulsion Medical Systems SE devices

Submission Details

510(k) Number K172259 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 27, 2017
Decision Date January 18, 2018
Days to Decision 175 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
50d slower than avg
Panel avg: 125d · This submission: 175d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DXG Computer, Diagnostic, Pre-programmed, Single-function
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1435
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Consultant

Maquet Cardiovascular
Mark Smith

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - DXG Computer, Diagnostic, Pre-programmed, Single-function

All 176
Devices cleared under the same product code (DXG) and FDA review panel - the closest regulatory comparables to K172259.
Argos Infinity (Rev. 1.0)
K253092 · Retia Medical Systems, Inc. · Feb 2026
VitalStream ART Connect
K251275 · Caretaker Medical · Sep 2025
Cogent™ Hemodynamic Monitoring System
K232048 · Icu Medical · Dec 2023
Hypotension Decision Assist Model HDA-OR2
K212529 · Directed Systems, Ltd. · Nov 2021
PulsioFlex Monitoring System with ProAQT Sensor
K192169 · Pulsion Medical Systems SE · Apr 2020
EV1000 Clinical Platform
K193179 · Edwards Lifesciences, LLC · Dec 2019